US FDA fast-tracks Achillion's hepatitis C drug candidate
USA-based Achillion Pharmaceuticals (Nasdaq: ACHN) says it has received Fast Track designation from the Food and Drug Administration for ACH-3102 as part of an interferon-free regimen for the treatment of chronic hepatitis C (HCV).
The market for hepatitis C treatments is expected to be worth around $15 billion by 2019, and the sector has attracted a fair amount of M&A activity relating to companies that are developing such treatments. This included Bristol-Myers Squibb planned $2.5 billion bid for Inhibitex and Gilead Sciences’ $11 billion bid for Pharmasset.
ACH-3102 is a pan-genotypic second-generation NS5A inhibitor against HCV that was discovered by Achillion and is currently being evaluated in a Phase I clinical trial. Earlier this year, Achillion was also granted a fast-track designation for another of its experimental hepatitis C drug, ACH-1625, is currently in a mid-stage development.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze